This is a regulatory disclosure submitted to both the National Stock Exchange of India Ltd. and BSE Limited regarding an upcoming board meeting and trading window closure.
The Board of Directors meeting is scheduled for Monday, August 10, 2026. The primary agenda is to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
Regarding trading restrictions, the Trading Window for dealing in the company's shares has been closed for all Directors, Key Managerial Personnel (KMPs), Designated Employees, and Connected Persons since July 01, 2026. This closure will remain in effect until the end of 48 hours after the financial results are declared and submitted to the Stock Exchanges.
The trading window closure was previously intimated via letter dated June 24, 2026, and is implemented pursuant to the Company's Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015.
The disclosure is made under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The document is digitally signed by Kajal Damania, who holds the position of Company Secretary and Compliance Officer at Sun Pharma Advanced Research Company Limited.